{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:25:46Z","timestamp":1793665546367,"version":"4.5.1"},"reference-count":18,"publisher":"University of Tokushima Faculty of Medicine","issue":"3.4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Med. Invest."],"published-print":{"date-parts":[[2023]]},"DOI":"10.2152\/jmi.70.516","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T22:15:10Z","timestamp":1699481710000},"page":"516-520","source":"Crossref","is-referenced-by-count":5,"title":["A case of successful treatment with eltrombopag for severe immune-related thrombocytopenia induced by atezolizumab:Case report"],"prefix":"10.2152","volume":"70","author":[{"given":"Saki","family":"Harada","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Imakura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seidai","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nokihara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Nishioka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan"},{"name":"Department of Community Medicine for Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"925","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Sa?ag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albig?s L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O:Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy:a descriptive observational study. Lancet Haematology 6:e48-e57, 2019","DOI":"10.1016\/S2352-3026(18)30175-3"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Michot JM, Lazarovici J, Tieu A, Champiat S, Voisin AL, Ebbo M, Godeau B, Michel M, Ribrag V, Lambotte O:Haematological Immune-Related Adverse Events with Immune Checkpoint Inhibitors, How to Manage? Eur. J. Cancer 122:72-90, 2019","DOI":"10.1016\/j.ejca.2019.07.014"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ito M, Kanda S, Yoshida T, Okuma Y, Jo H, Fukuhara S, Miyagi Maeshima A, Ohe Y:Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient. Lung Cancer 146:362-365, 2020","DOI":"10.1016\/j.lungcan.2020.05.015"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Bagley SJ, Kosteva JA, Evans TL, Langer CJ:Immune thrombocytopenia exacerbated by nivolumab in a patient with non-small-cell lung cancer. Cancer Treatment Communications. Volume 6:20-23, 2016","DOI":"10.1016\/j.ctrc.2016.02.009"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A;POPLAR Study Group:Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR):a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387:1837-46, 2016","DOI":"10.1016\/S0140-6736(16)00587-0"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Perez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Dur?n I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE 3rd, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Th?str?m A, Abidoye OO, Fine GD, Bajorin DF;IMvigor210 Study Group:Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma:a single-arm, multicentre, phase 2 trial. Lancet 389:67-76, 2017","DOI":"10.1016\/S0140-6736(16)32455-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O\u2019Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R:Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy:a single-arm, multicentre, phase 2 trial. Lancet 387:1909-20, 2016","DOI":"10.1016\/S0140-6736(16)00561-4"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ezponda Casaj?s A, Calvo Imirizaldu M, de Torres Tajes JP, Garc?a-Baiz?n A, Casta??n ?lvarez E, Cano Rafart D, Vivas P?rez I, Bastarrika Alema? G:Immune-related adverse events as predictors of response in cancer patients undergoing immunotherapy. Radiolog?a (English Edition) 62:131-138, 2020","DOI":"10.1016\/j.rxeng.2019.10.006"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficorella C, Buti S:Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clin Lung Cancer 20:237-247.e1, 2019","DOI":"10.1016\/j.cllc.2019.02.006"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Assi HA, Asch AS, Machiorlatti M, Vesely SK, Ibrahimi S:Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy. Future Sci OA 6:581, 2020","DOI":"10.2144\/fsoa-2020-0021"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Haddad TC, Zhao S, Li M, Patel SH, Johns A, Grogan M, Lopez G, Miah A, Wei L, Tinoco G, Riesenberg B, Li Z, Meara A, Bertino EM, Kendra K, Otterson G, Presley CJ, Owen DH:Immune checkpoint inhibitor-related thrombocytopenia:incidence, risk factors and effect on survival. Cancer Immunol Immunother 71:1157-1165, 2022","DOI":"10.1007\/s00262-021-03068-2"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Jia Li, Xubin Deng, Birong Wang, Weidong Li:Fatal outcome of atezolizumab in a patient with immune-mediated pneumonitis, thrombocytopenia, and cardiac dysfunction:A case report. Int J Clin Pharmacol Ther 57:607-611, 2019","DOI":"10.5414\/CP203448"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Tsukita Y, Miyauchi E, Fukudo M, Sasaki T, Ichinose M:Immunotherapy-related hepatitis and thrombocytopaenia induced by the very low dose of only 90 mg of atezolizumab. Eur J Cancer 133:22-24, 2020","DOI":"10.1016\/j.ejca.2020.04.008"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Y?lmaz A, Mirili C, Bilici M, Tekin SB:Possible atezolizumab-associated acute kidney injury and immune thrombocytopenia. J Oncol Pharm Pract 26(7):1791-1794, 2020","DOI":"10.1177\/1078155220913081"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Xie W, Hu N, Cao L:Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitrs in Lung Cancer:Case Report and Literature Review. Front Immunol 12:790051, 2021","DOI":"10.3389\/fimmu.2021.790051"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Liu X, Liang X, Liang J, Li Y, Wang J:Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer:Case Report and Literature Review. Front Oncol 10:530478, 2020","DOI":"10.3389\/fonc.2020.530478"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA;National Comprehensive Cancer Network:Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy:American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714-68, 2018","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Cooper N, Bussel J:The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 133:364-374, 2006","DOI":"10.1111\/j.1365-2141.2006.06024.x"}],"container-title":["The Journal of Medical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jmi\/70\/3.4\/70_516\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T05:22:54Z","timestamp":1715577774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jmi\/70\/3.4\/70_516\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":18,"journal-issue":{"issue":"3.4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2152\/jmi.70.516","relation":{},"ISSN":["1343-1420","1349-6867"],"issn-type":[{"value":"1343-1420","type":"print"},{"value":"1349-6867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]}}}